Vericel (VCEL) Cash from Operations (2010 - 2026)
Vericel (VCEL) posted Cash from Operations of 16191000.0 for Q2 2026, down 1.17% sequentially from 16383000.0 in Q1 2026, and up 97.11% YoY from 8214000.0 in Q2 2025.
Analysis
Vericel (VCEL) Cash from Operations (2010 - 2026) Analysis & Trends
Vericel has reported Cash from Operations for 17 years, with the latest figure at 16191000.0 in Q2 2026.
- Quarterly Cash from Operations rose 97.11% year-over-year to 16191000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 69670000.0 (up 47.48% YoY) and the FY2025 annual result came in at 51910000.0, down 10.75% from the prior year.
- Cash from Operations declined to 16191000.0 in Q2 2026 per VCEL's latest filing, from 16383000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 22242000.0 in Q4 2024 and troughed at 3143000.0 in Q2 2022.
- A 5-year average of 10869166.67 and a median of 9150000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 65.62% in 2022, then soared 224.4% in 2023.
- Over 5 years, Cash from Operations stood at 6975000.0 in 2022, then surged by 44.6% to 10086000.0 in 2023, then surged by 120.52% to 22242000.0 in 2024, then sank by 32.5% to 15014000.0 in 2025, then rose by 7.84% to 16191000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 16191000.0, 16383000.0, and 15014000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 16.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.19 Mn |
| Mar 31, 2026 | 16.38 Mn |
| Dec 31, 2025 | 15.01 Mn |
| Sep 30, 2025 | 22.08 Mn |
| Jun 30, 2025 | 8.21 Mn |
| Mar 31, 2025 | 6.60 Mn |
| Dec 31, 2024 | 22.24 Mn |
| Sep 30, 2024 | 10.18 Mn |
| Jun 30, 2024 | 18.54 Mn |
| Mar 31, 2024 | 7.20 Mn |
| Dec 31, 2023 | 10.09 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 10.20 Mn |
| Mar 31, 2023 | 7.86 Mn |
| Dec 31, 2022 | 6.98 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 3.47 Mn |
| Dec 31, 2021 | 10.55 Mn |
| Sep 30, 2021 | 3.63 Mn |